494 related articles for article (PubMed ID: 32957646)
21. A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia.
Hu CW; Qiu Y; Ligeralde A; Raybon AY; Yoo SY; Coombes KR; Qutub AA; Kornblau SM
Nat Biomed Eng; 2019 Nov; 3(11):889-901. PubMed ID: 30988472
[TBL] [Abstract][Full Text] [Related]
22. Integrated analysis of proteome, phosphotyrosine-proteome, tyrosine-kinome, and tyrosine-phosphatome in acute myeloid leukemia.
Tong J; Helmy M; Cavalli FM; Jin L; St-Germain J; Karisch R; Taylor P; Minden MD; Taylor MD; Neel BG; Bader GD; Moran MF
Proteomics; 2017 Mar; 17(6):. PubMed ID: 28176486
[TBL] [Abstract][Full Text] [Related]
23. Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation.
Cohen Freue GV; Meredith A; Smith D; Bergman A; Sasaki M; Lam KK; Hollander Z; Opushneva N; Takhar M; Lin D; Wilson-McManus J; Balshaw R; Keown PA; Borchers CH; McManus B; Ng RT; McMaster WR;
PLoS Comput Biol; 2013 Apr; 9(4):e1002963. PubMed ID: 23592955
[TBL] [Abstract][Full Text] [Related]
24. Analysis of mass spectrometry data in proteomics.
Matthiesen R; Jensen ON
Methods Mol Biol; 2008; 453():105-22. PubMed ID: 18712299
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of proteomics between acute myeloid leukemia and acute lymphoid leukemia].
Xiao P; Zeng YY; Nie YF; Lin W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1353-6. PubMed ID: 22169282
[TBL] [Abstract][Full Text] [Related]
26. Acute Myeloid Leukemia: Diagnosis and Management Based on Current Molecular Genetics Approach.
Suguna E; Farhana R; Kanimozhi E; Kumar PS; Kumaramanickavel G; Kumar CS
Cardiovasc Hematol Disord Drug Targets; 2018; 18(3):199-207. PubMed ID: 29766829
[TBL] [Abstract][Full Text] [Related]
27. Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management.
Stepczynska A; Schanstra JP; Mischak H
Bioanalysis; 2016; 8(5):439-55. PubMed ID: 26891752
[TBL] [Abstract][Full Text] [Related]
28. Identification of novel serum biomarker for the detection of acute myeloid leukemia based on liquid chromatography-mass spectrometry.
Wang D; Tan G; Wang H; Chen P; Hao J; Wang Y
J Pharm Biomed Anal; 2019 Mar; 166():357-363. PubMed ID: 30690249
[TBL] [Abstract][Full Text] [Related]
29. Optomechanical devices for deep plasma cancer proteomics.
Kosaka PM; Calleja M; Tamayo J
Semin Cancer Biol; 2018 Oct; 52(Pt 1):26-38. PubMed ID: 28867489
[TBL] [Abstract][Full Text] [Related]
30. In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies.
Pandey K; Mifsud NA; Lim Kam Sian TCC; Ayala R; Ternette N; Ramarathinam SH; Purcell AW
Mol Immunol; 2020 Jul; 123():7-17. PubMed ID: 32387766
[TBL] [Abstract][Full Text] [Related]
31. Standardization approaches in absolute quantitative proteomics with mass spectrometry.
Calderón-Celis F; Encinar JR; Sanz-Medel A
Mass Spectrom Rev; 2018 Nov; 37(6):715-737. PubMed ID: 28758227
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA biomarker identification for pediatric acute myeloid leukemia based on a novel bioinformatics model.
Yan W; Xu L; Sun Z; Lin Y; Zhang W; Chen J; Hu S; Shen B
Oncotarget; 2015 Sep; 6(28):26424-36. PubMed ID: 26317787
[TBL] [Abstract][Full Text] [Related]
33. Mass spectrometry-based proteomics in cell biology.
Walther TC; Mann M
J Cell Biol; 2010 Aug; 190(4):491-500. PubMed ID: 20733050
[TBL] [Abstract][Full Text] [Related]
34. Emerging mass spectrometry-based proteomics methodologies for novel biomedical applications.
Pino LK; Rose J; O'Broin A; Shah S; Schilling B
Biochem Soc Trans; 2020 Oct; 48(5):1953-1966. PubMed ID: 33079175
[TBL] [Abstract][Full Text] [Related]
35. Quantitative protein biomarker panels: a path to improved clinical practice through proteomics.
Hartl J; Kurth F; Kappert K; Horst D; Mülleder M; Hartmann G; Ralser M
EMBO Mol Med; 2023 Apr; 15(4):e16061. PubMed ID: 36939029
[TBL] [Abstract][Full Text] [Related]
36. Platforms and Pipelines for Proteomics Data Analysis and Management.
Codrea MC; Nahnsen S
Adv Exp Med Biol; 2016; 919():203-215. PubMed ID: 27975218
[TBL] [Abstract][Full Text] [Related]
37. Analyzing Cerebrospinal Fluid Proteomes to Characterize Central Nervous System Disorders: A Highly Automated Mass Spectrometry-Based Pipeline for Biomarker Discovery.
Núñez Galindo A; Macron C; Cominetti O; Dayon L
Methods Mol Biol; 2019; 1959():89-112. PubMed ID: 30852817
[TBL] [Abstract][Full Text] [Related]
38. Proteomics methods for subcellular proteome analysis.
Drissi R; Dubois ML; Boisvert FM
FEBS J; 2013 Nov; 280(22):5626-34. PubMed ID: 24034475
[TBL] [Abstract][Full Text] [Related]
39. Automated Proteomics Workflows for High-Throughput Library Generation and Biomarker Detection Using Data-Independent Acquisition.
Paramasivan S; Morrison JL; Lock MC; Darby JRT; Barrero RA; Mills PC; Sadowski P
J Proteome Res; 2023 Jun; 22(6):2018-2029. PubMed ID: 37219895
[TBL] [Abstract][Full Text] [Related]
40. Combining bioinformatics and MS-based proteomics: clinical implications.
Acosta-Martin AE; Lane L
Expert Rev Proteomics; 2014 Jun; 11(3):269-84. PubMed ID: 24720436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
